Home
GKOS
GKOS News

Latest Glaukos Corporation (GKOS) News on March 31, 2025

Argus Research

6 days ago

GKOS: Raising target price to $86.00

Breakeven On The Horizon For Glaukos Corporation (NYSE:GKOS)

Simply Wall St.

7 days ago

Breakeven On The Horizon For Glaukos Corporation (NYSE:GKOS)

Here's Why You Should Retain Glaukos Stock in Your Portfolio

Zacks

18 days ago

Here's Why You Should Retain Glaukos Stock in Your Portfolio

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Business Wire

20 days ago

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Is Glaukos Corporation (GKOS) the Best Medical Technology Stock to Buy According to Analysts?

Insider Monkey

a month ago

Is Glaukos Corporation (GKOS) the Best Medical Technology Stock to Buy According to Analysts?

Argus Research

a month ago

GKOS: Lowering target price to $90.00

MT Newswires

a month ago

Glaukos Insider Sold Shares Worth $2,497,335, According to a Recent SEC Filing

GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?

Zacks

a month ago

GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?

Argus Research

a month ago

GKOS: Lowering target price to $96.00

MT Newswires

a month ago

Glaukos's Corneal Disease Drug Accepted for FDA Review

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Business Wire

a month ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

We're Not Worried About Glaukos' (NYSE:GKOS) Cash Burn

Simply Wall St.

a month ago

We're Not Worried About Glaukos' (NYSE:GKOS) Cash Burn

Wingstop Stock’s Dip Is an Opportunity, Analyst Says. Plus, Devon Energy, Cadence Design, and More.

Barrons.com

a month ago

Wingstop Stock’s Dip Is an Opportunity, Analyst Says. Plus, Devon Energy, Cadence Design, and More.

GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline

Zacks

a month ago

GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline

Glaukos Corp (GKOS) Q4 2024 Earnings Call Highlights: Record Sales and Strategic Growth Amid ...

GuruFocus.com

a month ago

Glaukos Corp (GKOS) Q4 2024 Earnings Call Highlights: Record Sales and Strategic Growth Amid ...

Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

Zacks

a month ago

Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

Associated Press Finance

a month ago

Glaukos: Q4 Earnings Snapshot

MT Newswires

a month ago

Glaukos Q4 Non-GAAP Loss Narrows, Sales Rise

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Business Wire

a month ago

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz

TipRanks

a month ago

Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz

What To Expect From Glaukos Corp (GKOS) Q4 2024 Earnings

GuruFocus.com

a month ago

What To Expect From Glaukos Corp (GKOS) Q4 2024 Earnings

MT Newswires

a month ago

Mizuho Upgrades Glaukos Corp to Outperform From Neutral, Adjusts Price Target to $200 From $140

What to Expect From These 3 MedTech Stocks This Earnings Season?

Zacks

a month ago

What to Expect From These 3 MedTech Stocks This Earnings Season?

Argus Research

a month ago

GKOS: Raising target price to $138.00

What Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings

Zacks

a month ago

What Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Zacks

2 months ago

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Argus Research

2 months ago

GKOS: Lowering target price to $139.00

Mesa Labs (MLAB) Q3 Earnings and Revenues Beat Estimates

Zacks

2 months ago

Mesa Labs (MLAB) Q3 Earnings and Revenues Beat Estimates

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 90% Above Its Share Price

Simply Wall St.

2 months ago

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 90% Above Its Share Price

Argus Research

2 months ago

GKOS: Raising target price to $140.00

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Business Wire

2 months ago

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock?

Zacks

2 months ago

NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock?

Argus Research

2 months ago

GKOS: Raising target price to $139.00

GKOS Stock Gains Following Positive Study Data on iDose Platform

Zacks

3 months ago

GKOS Stock Gains Following Positive Study Data on iDose Platform

Argus Research

3 months ago

GKOS: Lowering target price to $133.00

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Business Wire

3 months ago

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Here's Why You Should Add Glaukos Stock to Your Portfolio Now

Zacks

3 months ago

Here's Why You Should Add Glaukos Stock to Your Portfolio Now

Glaukos Reaches 52-Week High: What's Driving the Stock's Rally?

Zacks

3 months ago

Glaukos Reaches 52-Week High: What's Driving the Stock's Rally?

Glaukos price target raised to $157 from $149 at BTIG

TipRanks

3 months ago

Glaukos price target raised to $157 from $149 at BTIG

MT Newswires

3 months ago

Stifel Adjusts Price Target on Glaukos to $175 From $153, Keeps Buy Rating

Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA

Zacks

3 months ago

Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA

MT Newswires

3 months ago

Glaukos Insider Sold Shares Worth $498,716, According to a Recent SEC Filing

MT Newswires

3 months ago

Glaukos Insider Sold Shares Worth $1,502,800, According to a Recent SEC Filing

Argus Research

3 months ago

GKOS: Raising target price to $130.00

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Business Wire

3 months ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

The three-year returns have been stellar for Glaukos (NYSE:GKOS) shareholders despite underlying losses increasing

Simply Wall St.

3 months ago

The three-year returns have been stellar for Glaukos (NYSE:GKOS) shareholders despite underlying losses increasing

Glaukos price target raised to $185 from $152 at Truist

TipRanks

3 months ago

Glaukos price target raised to $185 from $152 at Truist

MT Newswires

3 months ago

Truist Securities Adjusts Price Target on Glaukos to $185 From $152, Keeps Buy Rating

Argus Research

3 months ago

GKOS: Raising target price to $128.00

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Business Wire

3 months ago

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen

Zacks

4 months ago

The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen

Here's Why You Should Add Glaukos Stock to Your Portfolio Now

Zacks

4 months ago

Here's Why You Should Add Glaukos Stock to Your Portfolio Now

5 Medical Device Stocks That Survived the 2024 Market Volatility

Zacks

4 months ago

5 Medical Device Stocks That Survived the 2024 Market Volatility

MT Newswires

4 months ago

Citigroup Upgrades Glaukos to Buy From Neutral, Raises Price Target to $162 From $132

Argus Research

4 months ago

GKOS: What does Argus have to say about GKOS?

Glaukos initiated with a Buy at UBS

TipRanks

4 months ago

Glaukos initiated with a Buy at UBS

MT Newswires

4 months ago

UBS Initiates Glaukos at Buy With $182 Price Target

Argus Research

4 months ago

GKOS: Lowering target price to $120.00

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Benzinga

4 months ago

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

MT Newswires

4 months ago

Morgan Stanley Downgrades Glaukos Corp to Underweight

Argus Research

4 months ago

GKOS: Lowering target price to $121.00

Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally?

Zacks

4 months ago

Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally?

Argus Research

5 months ago

GKOS: Raising target price to $121.00

Glaukos Announces Participation in Upcoming Investor Conferences

Business Wire

5 months ago

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (NYSE:GKOS) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Simply Wall St.

5 months ago

Glaukos Corporation (NYSE:GKOS) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Glaukos price target raised to $145 from $135 at Wells Fargo

TipRanks

5 months ago

Glaukos price target raised to $145 from $135 at Wells Fargo

Glaukos Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Glaukos Third Quarter 2024 Earnings: Beats Expectations

Argus Research

5 months ago

GKOS: Lowering target price to $115.00

Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

5 months ago

Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Thomson Reuters StreetEvents

5 months ago

Q3 2024 Glaukos Corp Earnings Call

GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates

Zacks

5 months ago

GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates

Glaukos Corp (GKOS) Q3 2024 Earnings Call Highlights: Record Sales and Raised Guidance Amid ...

GuruFocus.com

5 months ago

Glaukos Corp (GKOS) Q3 2024 Earnings Call Highlights: Record Sales and Raised Guidance Amid ...

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

Zacks

5 months ago

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

MT Newswires

5 months ago

Glaukos Q3 Non-GAAP Loss Narrows, Sales Increase; 2024 Sales Guidance Raised

Associated Press Finance

5 months ago

Glaukos: Q3 Earnings Snapshot

Glaukos Announces Third Quarter 2024 Financial Results

Business Wire

5 months ago

Glaukos Announces Third Quarter 2024 Financial Results

Earnings To Watch: Glaukos Corp (GKOS) Reports Q3 2024 Result

GuruFocus.com

5 months ago

Earnings To Watch: Glaukos Corp (GKOS) Reports Q3 2024 Result

Masimo (MASI) Reports Next Week: Wall Street Expects Earnings Growth

Zacks

5 months ago

Masimo (MASI) Reports Next Week: Wall Street Expects Earnings Growth

Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

5 months ago

Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa

Zacks

5 months ago

GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa

Glaukos eyes FDA approval for ocular therapy after Phase III win

Pharmaceutical Technology

5 months ago

Glaukos eyes FDA approval for ocular therapy after Phase III win

MT Newswires

5 months ago

Glaukos Reports Positive Results From Potential Eye Disease Treatment Study

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Business Wire

5 months ago

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Business Wire

6 months ago

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

MT Newswires

6 months ago

Truist Raises Price Target on Glaukos to $152 From $145, Maintains Buy Rating

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Business Wire

6 months ago

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Argus Research

6 months ago

GKOS: Raising target price to $112.00

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Zacks

6 months ago

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally?

Zacks

6 months ago

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally?

Glaukos Stocks Rides on Strong Product Demand Amid Competition

Zacks

7 months ago

Glaukos Stocks Rides on Strong Product Demand Amid Competition

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Zacks

7 months ago

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Here’s Why Glaukos (GKOS) Appreciated in Q2

Insider Monkey

7 months ago

Here’s Why Glaukos (GKOS) Appreciated in Q2

Better Than Expected Earnings Results Boosted Glaukos Corp (GKOS) in Q2

Insider Monkey

7 months ago

Better Than Expected Earnings Results Boosted Glaukos Corp (GKOS) in Q2

Argus Research

7 months ago

GKOS: Raising target price to $111.00

MT Newswires

7 months ago

Needham Raises Price Target on Glaukos to $149 From $137, Maintains Buy Rating

MT Newswires

7 months ago

Glaukos Insider Sold Shares Worth $646,791, According to a Recent SEC Filing

Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?

Zacks

7 months ago

Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?

Argus Research

7 months ago

GKOS: What does Argus have to say about GKOS?

Glaukos Announces Participation in Upcoming Investor Conferences

Business Wire

7 months ago

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (NYSE:GKOS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$133

Simply Wall St.

8 months ago

Glaukos Corporation (NYSE:GKOS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$133

Share on Social Networks: